Comparison of polymethoxyethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts

Abstract

Objectives: The relative benefits of strategic leukofiltration on polymer-coated and low-dose heparin protocol on heparin-coated circuits were studied across EuroSCORE patient risk strata for three different cohorts.

Methods: In a prospective, randomized study, 270 patients undergoing coronary artery bypass grafting were allocated into three groups (n = 90): Group 1 -polymethoxyethylacrylate-coated circuits+leukocyte filters; Group 2 -polypeptide-based heparin-bonded circuits with reduced heparinization; and Group 3 -Control: uncoated circuits. Each group was further divided into three subgroups (n = 30), with respect to low- (EuroSCORE 0-2), medium- (3-5), and high- (6+) risk patients. Blood samples were collected at T1: following induction of anesthesia; T2: following heparin administration; T3: 15 min after CPB; T4: before cessation of CPB; T5: 15 min after protamine reversal; and T6: ICU.

Results: In high-risk cohorts, leukocyte counts demonstrated significant differences at T4 and T5 in Group 1, and at T4 in Group 2. Platelet counts were preserved significantly better at T4 and T5 in both groups (p <0.05 versus control). Serum IL-2 and C3a levels were significantly lower at T3, T4 and T5 in Group 1, and T4 and T5 in Group 2 (p <0.05). Postoperative bleeding, respiratory support time and incidence of atrial fibrillation were lower in the study groups versus control. Cell counts on filter mesh and heparin-coated fibers/circuits were significantly higher in the high-risk cohorts versus uncoated fibers. Phagocytic capacity increased on filter mesh, especially in high-risk specimens. SEM evaluation demonstrated better preserved coated circuits.

Conclusion: Leukofiltration and coating reduced platelet adhesion, protein adsorption, atrial fibrillation and reduced heparinization acted via modulation of systemic inflammatory response in high-risk groups.

Get full access to this article

View all access options for this article.

References

Tayama E , Hayashida N , Akasu K et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system . Artif Organs 2000; 24: 618-623 .

Ovrum E , Tangen G , Oystese R , Ringdal MAL , Istad R. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations . J Thorac Cardiovasc Surg 2001; 121: 324-330 .

Videm V , Mollnes TE , Fosse E et al. Heparin-coated cardiopulmonary bypass equipment: biocompatibility markers and development of complications in a high risk population . J Thorac Cardiovasc Surg 1999; 117: 794-802 .

Ovrum E , Tangen G , Oystese R , Ringdal ML , Istad R. Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery . J Card Surg 2003; 18: 140-146 .

Ortolano GA , Aldea GS , Lilly K et al. A review of leukofiltration in cardiac surgery: the time course of reperfusion injury may facilitate study design of anti-inflammatory effects . Perfusion 2002; 17: S53-S62 .

Ranucci M , Mazzucco A , Pessotto R et al. Heparin-coated circuits for high risk patients: a multicenter, prospective randomized trial . Ann Thorac Surg 1999; 67: 994-1000 .

Roques F , Nashef SA , Michel P et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients . Eur J Cardiothorac Surg 1999; 15: 816-823 .

Repo H , Jansson SE , Leirisalo-Repo M. Flow cyto-metric determination of CD11b upregulation in vivo . J Immunol Methods 1993; 164: 193-202 .

Ulusoy A , Onur MA. Measurement of in vitro phagocytic activity using functional groups carrying mono-disperse poly(glycidyl methacrylate) microspheres in rat blood . J Biomater Sci Polymer Edn 2003; 14: 1299-1310 .

10.

Gunaydin S. Clinical significance of coated extracorporeal circuits: a review of novel technologies . Perfusion 2004; 19: S33-S41 .

11.

Gunaydin S. Emerging technologies in biocompatible surface modifying additives: quest for physiologic cardiopulmonary bypass . Curr Med Chem -Cardiovasc Hematol Agents 2004; 2: 187-196 .

12.

Scholz M , Simon A , Matheis G et al . Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery . Inflamm Res 2002; 51: 363-368 .

13.

Muehrcke DD , McCarthy PM , Kottke-Marchant K et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial . J Thorac Cardiovasc Surg 1996; 112: 472-483 .

14.

Videm V , Mollnes TE , Bergh K et al. Heparin-coated cardiopulmonary bypass equipment: mechanisms for reduced complement activation in vivo . J Thorac Cardiovasc Surg 1999; 117: 803-809 .

15.

Palatianos GM , Foroulis CN , Vassili MI et al. A prospective, double blind study on the efficacy of the Bioline surface heparinized extracorporeal perfusion circuit . Ann Thorac Surg 2003; 76: 129-135 .

16.

Tayama E , Hayashida N , Akasu K et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin-bonded bioline system . Artif Organs 2000; 24: 618-623 .

17.

McCarthy PM , Yared JP , Foster RC , Ogella DA , Borsh JA , Cosgrove DM. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations . Ann Thorac Surg 1999; 67: 1268-1273 .

18.

Ovrum E , Brosstad F , Holen EA , Tangen G , Adelnoor M. Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass . Circulation 1995; 92: 2579-2584 .

19.

Kirklin JK , Chenoweth DE , Naftel DC et al . Effects of protamine administration after cardiopulmonary bypass on complement, blood elements, and the hemodynamic state . Ann Thorac Surg 1986; 41: 193-199 .

20.

Palatianos GM , Balentine G , Papadakis EG et al . Neutrophil depletion reduces myocardial reperfusion morbidity . Ann Thorac Surg 2004; 77: 956-961 .

21.

Baksaas ST , Flom-Halvorsen HI , Ovrum E et al . Leukocyte filtration during cardiopulmonary reperfusion in coronary artery bypass surgery . Perfusion 1999; 14: 107-117 .

22.

Sahlman A , Ahonen J , Salo JA , Ramo OJ. No impact of a leukocyte depleting arterial line filter on patients’ recovery after cardiopulmonary bypass . Acta Anaesthesiol Scand 2001; 45: 558-563 .

23.

Gunaydin S , McCusker K , Vijay V et al. Clinical significance of strategic leukofiltration in different risk cohorts undergoing cardiac surgery . Filtration 2005; 1: 95-106 .

24.

Salamonsen RF , Anderson J , Anderson M , Bailey M , Magrin G , Rosenfeldt F. Total leukocyte control for elective coronary bypass surgery does not improve short term outcome . Ann Thorac Surg 2005; 79: 2032-2039 .

25.

Gunaydin S , Sari T , McCusker K et al. Clinical evaluation strategic leukofiltration with surface modification: enhanced preservation or fantasy . Filtration 2005; 1: 57-67 .

26.

Gunaydin S , McCusker K , Vijay V. Strategic leukofiltration in cardiac surgery . Curr Med Chem -Cardiovasc Hematol Agents 2005; 3: 173-179 .

27.

Ilmakunnas M , Pesonen EJ , Ahonen JA , Ramo J , Siitonen S , Repo H. Activation of neutrophils and monocytes by a leukocyte depleting filter used throughout cardiopulmonary bypass . J Thorac Cardiovasc Surg 2005; 129: 851-859 .